Is This Latecomer a Better Buy Than Moderna and Pfizer?

Moderna (NASDAQ: MRNA) and Pfizer (NYSE: PFE) dominate the coronavirus vaccine market. Each has generated quarterly vaccine revenue in the billions. And they expect to report annual vaccine revenue of as much as $18 billion and $36 billion, respectively. Johnson & Johnson also sells a coronavirus vaccine. But the company has remained a distant rival since that product's authorization.

But the vaccine market soon may welcome another competitor. And that competitor has a potential vaccine that could carve out a decent share of the market. Now, the question is whether, right now, this latecomer represents a better buy than today's leaders. Let's find out.

Image source: Getty Images.

Continue reading

Source Fool.com